Icosapent ethyl is generally well tolerated and adverse effects are unrelated to treatment.
Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. FDA approved on July 26, 2012.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Apixaban. |
| Dasatinib | Dasatinib may increase the anticoagulant activities of Icosapent ethyl. |
| Ursodeoxycholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Hyodeoxycholic Acid. |
| Glucosamine | Glucosamine may increase the antiplatelet activities of Icosapent ethyl. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ibritumomab tiuxetan. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Obinutuzumab. |
| Pentoxifylline | Pentoxifylline may increase the antiplatelet activities of Icosapent ethyl. |
| Rivaroxaban | Icosapent ethyl may increase the anticoagulant activities of Rivaroxaban. |
| Tipranavir | Tipranavir may increase the antiplatelet activities of Icosapent ethyl. |
| Urokinase | Icosapent ethyl may increase the anticoagulant activities of Urokinase. |
| Ibrutinib | Icosapent ethyl may increase the antiplatelet activities of Ibrutinib. |
| Pentosan polysulfate | The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Icosapent ethyl. |
| Limaprost | Limaprost may increase the antiplatelet activities of Icosapent ethyl. |
| Omega-3 fatty acids | Omega-3 fatty acids may increase the antiplatelet activities of Icosapent ethyl. |
| Tositumomab | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tositumomab. |
| Lepirudin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lepirudin. |
| Bivalirudin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bivalirudin. |
| Alteplase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Alteplase. |
| Reteplase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Reteplase. |
| Anistreplase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Anistreplase. |
| Tenecteplase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Tenecteplase. |
| Abciximab | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Abciximab. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Drotrecogin alfa. |
| Streptokinase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Streptokinase. |
| Dicoumarol | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dicoumarol. |
| Argatroban | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Argatroban. |
| Ardeparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ardeparin. |
| Phenindione | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Phenindione. |
| Fondaparinux | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Fondaparinux. |
| Warfarin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Phenprocoumon. |
| Dipyridamole | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dipyridamole. |
| Heparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Heparin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Enoxaparin. |
| Epoprostenol | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Epoprostenol. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Coumarin. |
| Ximelagatran | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ximelagatran. |
| Desmoteplase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Desmoteplase. |
| Defibrotide | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Defibrotide. |
| Ancrod | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ancrod. |
| Beraprost | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Beraprost. |
| Prasugrel | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Prasugrel. |
| Sulodexide | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Sulodexide. |
| Semuloparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Semuloparin. |
| Idraparinux | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Idraparinux. |
| Cangrelor | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cangrelor. |
| Astaxanthin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Astaxanthin. |
| Otamixaban | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Otamixaban. |
| Amediplase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Amediplase. |
| Danaparoid | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Danaparoid. |
| Dalteparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dalteparin. |
| Tinzaparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Tinzaparin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ethyl biscoumacetate. |
| Nadroparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Nadroparin. |
| Triflusal | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Triflusal. |
| Ticagrelor | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ticagrelor. |
| Ditazole | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ditazole. |
| Vorapaxar | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Vorapaxar. |
| Edoxaban | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Edoxaban. |
| Sodium citrate | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Sodium citrate. |
| Dextran | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dextran. |
| Bemiparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bemiparin. |
| Parnaparin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Parnaparin. |
| Desirudin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Desirudin. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Antithrombin Alfa. |
| Protein C | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Protein C. |
| Antithrombin III human | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Antithrombin III human. |
| Letaxaban | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Letaxaban. |
| Darexaban | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Darexaban. |
| Betrixaban | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Betrixaban. |
| Nafamostat | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Nafamostat. |
| Monteplase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Monteplase. |
| Gabexate | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gabexate. |
| Fluindione | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Fluindione. |
| Protein S human | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Protein S human. |
| Brinase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Brinase. |
| Clorindione | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Tioclomarol. |
| Melagatran | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Melagatran. |
| Saruplase | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Saruplase. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with (S)-Warfarin. |
| Tocopherylquinone | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Tocopherylquinone. |
| Dabigatran | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dabigatran. |
| Troxerutin | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Troxerutin. |